PHVS vs RCUS
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
PHVS · Pharvaris$34.39 ▲ 5.72%
RCUS · Arcus Biosciences$18.28 ▲ 3.34%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- PHVS +52.0%
- RCUS -6.1%
Head to head
| Metric | PHVS | RCUS |
|---|---|---|
| Price | $34.39 | $18.28 |
| Change today | ▲ 5.72% | ▲ 3.34% |
| Market cap | $2.41B | $2.63B |
| Return, 3 months | -1.3% | -36.4% |
| Return, year to date | +23.9% | -23.3% |
| Return, 1 year | +59.3% | -5.3% |
| P/E (TTM) | – | – |
| P/B | 7.2 | 7.4 |
| P/E percentile vs own 5y | 8th | 51st |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | -74.4% |
| Net profit growth (YoY) | -5.2% | – |
| Gross margin | – | – |
| Operating margin | – | -415.4% |
| Net margin | – | -393.2% |
| Return on equity | -70.5% | -90.8% |
| Analyst target vs. price | +78.3% | +122.6% |
| Analyst buy share | 100% | 73% |
| RSI (14) | 59 | 37 |
| 30-day volatility | 45.0% | 82.7% |
| Max drawdown, 1 year | -28.6% | -44.0% |
| Trend read | Strong uptrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- RCUS is the largest of the group by market value.
- PHVS has returned the most over the past year.
- PHVS has been the calmest stock over the last 30 days.